Duane Catherine, O'Dwyer Michael, Glavey Siobhan
Department of Haematology, Beaumont Hospital, D09 V2N0 Dublin, Ireland.
Department of Haematology, University of Galway, H91 TK33 Galway, Ireland.
Cancers (Basel). 2023 May 6;15(9):2633. doi: 10.3390/cancers15092633.
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic strategies, particularly T cell-based agents have changed the treatment landscape for patients with relapsed and refractory disease. Adoptive cellular therapies include chimeric antigen receptor (CAR) T cells, which have emerged as a highly promising therapy, particularly for patients with refractory disease. Other adoptive cellular approaches currently in trials include T cell receptor-based therapy (TCR), and the expansion of CAR technology to natural killer (NK) cells. In this review we explore the emerging therapeutic field of adoptive cellular therapy for MM, with a particular focus on the clinical impact of these therapies for patients with high-risk myeloma.
尽管多发性骨髓瘤（MM）的治疗取得了显著进展，但它大多仍无法治愈，这凸显了对新治疗方法的需求。具有高风险疾病特征的患者预后特别差，对当前一线治疗的反应有限。免疫治疗策略的最新发展，特别是基于T细胞的药物，已经改变了复发和难治性疾病患者的治疗格局。过继性细胞疗法包括嵌合抗原受体（CAR）T细胞，它已成为一种非常有前景的疗法，特别是对于难治性疾病患者。目前正在试验的其他过继性细胞方法包括基于T细胞受体的疗法（TCR），以及将CAR技术扩展到自然杀伤（NK）细胞。在这篇综述中，我们探讨了MM过继性细胞疗法这一新兴治疗领域，特别关注这些疗法对高危骨髓瘤患者的临床影响。
